Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	54,313	63,809	55,222	43,529	50,178
Short-Term Investments	-	3,330	3,199	2,812	2,633
Trading Asset Securities	0.16	0.55	0.5	11.75	39.14
Cash & Short-Term Investments	54,314	67,139	58,421	46,353	52,850
Cash Growth	-19.10%	14.92%	26.04%	-12.29%	27.68%
Accounts Receivable	201,479	185,790	171,204	172,576	146,049
Other Receivables	-	4,007	3,703	3,698	3,399
Receivables	201,479	189,797	174,908	176,273	149,448
Inventory	62,353	60,028	60,926	51,500	47,085
Restricted Cash	-	1,850	1,488	-	-
Other Current Assets	29,303	18,022	23,665	16,796	18,226
Total Current Assets	347,448	336,835	319,406	290,922	267,610
Property, Plant & Equipment	19,632	19,898	19,647	19,408	18,896
Long-Term Investments	10,894	10,551	9,840	9,184	8,473
Goodwill	-	7,186	7,156	7,199	7,287
Other Intangible Assets	8,949	2,830	2,941	3,116	3,361
Long-Term Accounts Receivable	111.7	793.92	1,123	874.58	870
Long-Term Deferred Tax Assets	2,408	1,964	1,980	1,787	1,602
Long-Term Deferred Charges	-	180.02	74.44	76.61	81.26
Other Long-Term Assets	3,388	3,158	2,607	2,845	3,057
Total Assets	392,831	383,395	364,775	335,412	311,237
Accounts Payable	151,109	146,632	137,085	128,431	112,632
Accrued Expenses	20,502	8,832	9,571	8,354	7,760
Current Portion of Long-Term Debt	62,729	54,730	52,997	55,152	54,959
Current Portion of Leases	1,761	1,797	1,636	1,548	1,406
Current Income Taxes Payable	1,447	1,775	1,703	1,614	1,470
Current Unearned Revenue	6,829	6,399	10,396	6,086	7,324
Other Current Liabilities	5,999	21,326	21,574	18,122	18,426
Total Current Liabilities	250,376	241,491	234,963	219,307	203,977
Long-Term Debt	8,637	13,834	11,750	8,419	8,919
Long-Term Leases	3,259	3,421	3,207	3,250	3,243
Long-Term Unearned Revenue	54.78	448.24	493.85	462.74	453.87
Long-Term Deferred Tax Liabilities	638.75	788.38	936.74	1,023	1,112
Other Long-Term Liabilities	2,765	2,727	2,975	2,910	3,189
Total Liabilities	266,144	263,076	254,706	235,758	221,289
Common Stock	3,121	3,121	3,121	3,121	3,121
Additional Paid-In Capital	-	24,641	24,641	24,641	24,641
Retained Earnings	53,745	51,197	44,701	38,516	32,908
Treasury Stock	-3.84	-3.84	-3.84	-3.84	-3.84
Comprehensive Income & Other	22,022	-4,373	-4,391	-4,388	-4,308
Total Common Equity	78,884	74,582	68,069	61,886	56,359
Minority Interest	47,804	45,737	42,001	37,768	33,588
Shareholders' Equity	126,687	120,319	110,069	99,654	89,947
Total Liabilities & Equity	392,831	383,395	364,775	335,412	311,237
Total Debt	76,386	73,782	69,590	68,368	68,527
Net Cash (Debt)	-22,073	-6,643	-11,169	-22,016	-15,677
Net Cash Per Share	-7.08	-2.13	-3.58	-7.05	-5.04
Filing Date Shares Outstanding	3,121	3,121	3,121	3,121	3,121
Total Common Shares Outstanding	3,121	3,121	3,121	3,121	3,121
Working Capital	97,072	95,344	84,443	71,616	63,633
Book Value Per Share	25.28	23.90	21.81	19.83	18.06
Tangible Book Value	69,935	64,566	57,972	51,571	45,711
Tangible Book Value Per Share	22.41	20.69	18.58	16.53	14.65
Buildings	-	12,997	12,907	12,127	11,346
Machinery	-	10,099	9,169	8,412	7,605
Construction In Progress	-	505.47	800.05	718.53	519.85

Updated Sep 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.